Meeting
2023 ASCO Annual Meeting
Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.
Authors
Stephen V. Liu
Georgetown University, Washington, DC
Stephen V. Liu , Jesse Sussell , Denise Boudreau , Robert Schuldt , Joanna Harton , Ilze Bara , An Pregenzer , Jason Porter
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9077)
DOI
10.1200/JCO.2023.41.16_suppl.9077
Abstract #
9077
Poster Bd #
65
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.
First Author: Eric Nadler
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang